In 2011, the U.S. Food and Drug Administration (FDA) issued a safety communication stating the anti-nausea drug Zofran may increase the risk of potentially fatal abnormal heart rhythms. Patients at particular risk of changes in the electrical activity of the heart include those with underlying heart conditions.